本文選題：大腸癌　切入點(diǎn)：FGF3　出處：《河北醫(yī)科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:大腸癌是全世界最常見的高發(fā)惡性腫瘤之一,近年來大腸癌的發(fā)病率呈現(xiàn)出上升趨勢(shì)。大腸癌的發(fā)病原因復(fù)雜并未完全闡明,但多數(shù)學(xué)者認(rèn)為大腸癌的發(fā)生是由多種因素及多種基因相互作用而逐步發(fā)展的結(jié)果。目前有大量研究表明,人類多數(shù)腫瘤的發(fā)生、發(fā)展過程均與FGF3成纖維細(xì)胞生長(zhǎng)因子3基因表達(dá)相關(guān),并與腫瘤的惡性分化及預(yù)后有關(guān)。本實(shí)驗(yàn)通過實(shí)時(shí)熒光定量聚合酶鏈反應(yīng)(real-time PCR)檢測(cè)大腸癌患者癌組織和其對(duì)應(yīng)癌旁組織中FGF3 mRNA的相對(duì)表達(dá)量水平,通過對(duì)實(shí)驗(yàn)數(shù)據(jù)及臨床病理資料的分析,研究FGF3 mRNA與大腸癌之間的關(guān)系,為深入了解FGF3在大腸癌發(fā)病過程中發(fā)揮的作用提供理論依據(jù)。方法:1收集2015年9月~2016年10月51對(duì)來自河北醫(yī)科大學(xué)第一醫(yī)院普外科大腸癌及對(duì)應(yīng)癌旁組織手術(shù)標(biāo)本。大腸癌組織定義為病理證實(shí)的無壞死、穿孔及潰瘍的原發(fā)大腸癌組織;癌旁組織定義為距離腫瘤邊緣5cm以上的病理證實(shí)的非癌組織,并且無壞死、穿孔及潰瘍的大腸組織。新鮮組織標(biāo)本離體后迅速置于冷處理后的1.5ml EP管中,并放入-80℃超低溫冰箱中保存。51名患者術(shù)前從未進(jìn)行任何方案的化學(xué)治療和放射治療。2大腸癌組織及癌旁組織中總RNA的提取是嚴(yán)格按照美國(guó)Invirotrogen公司Trizol試劑說明書步驟方法進(jìn)行提取操作。然后按照美國(guó)genecopoeia公司反轉(zhuǎn)錄試劑盒說明書步驟進(jìn)行反轉(zhuǎn)錄,獲得cDNA。3應(yīng)用real-time PCR方法檢測(cè)51對(duì)大腸癌組織及對(duì)應(yīng)癌旁組織的CT值,以GAPDH為內(nèi)參,用2-△CT方法計(jì)算FGF3mRNA在大腸癌組織、癌旁組織中的相對(duì)表達(dá)量。比較兩組間表達(dá)差異,然后再以不同的病理資料進(jìn)行分組,比較不同組之間癌組織相對(duì)表達(dá)量的差異。4采用SPSS19.0及GraphPad Prism 5.0統(tǒng)計(jì)軟件,對(duì)實(shí)驗(yàn)結(jié)果進(jìn)行分析,計(jì)量資料以中位數(shù)(四分位數(shù))表示,兩組間配對(duì)樣本采用非參數(shù)檢驗(yàn)。以P0.05表示差異存在有統(tǒng)計(jì)學(xué)意義。結(jié)果:1FGF3在51例大腸癌組織中相對(duì)表達(dá)量0.00054(0.00011,0.00154),癌旁組織中表達(dá)量0.00306(0.00096,0.01170),可見FGF3在大腸癌組織中的表達(dá)明顯低于癌旁組織的表達(dá),差異有統(tǒng)計(jì)學(xué)意義(p0.05,見fig.1)。251位患者平均年齡約為65歲,以年齡分組,其中小于65歲的患者組大腸癌組織中FGF3的相對(duì)表達(dá)量為0.00087(0.00011,0.00234),年齡等于或大于65歲的患者組大腸癌組織中FGF3的相對(duì)表達(dá)量為0.00050(0.00011,0.00116)。小于65歲的患者組大腸癌組織中FGF3的相對(duì)表達(dá)量稍高于大于或等于65歲的患者組,但兩組之間無統(tǒng)計(jì)學(xué)差異(p0.05,見fig.2、table.1)。3以性別分組,51例直腸癌患者分為男性組和女性組,分別為33名男性患者和18名女性患者,男性組大腸癌組織中FGF3的相對(duì)表達(dá)量為0.00040(0.00011,0.00146),女性組大腸癌組織中FGF3的相對(duì)表達(dá)量為0.00057(0.00017,0.00246),女性組癌組織中FGF3的相對(duì)表達(dá)量稍高于男性組,但無統(tǒng)計(jì)學(xué)差異(p0.05,見fig.3、table.1)。451例直腸癌患者包括22名有淋巴結(jié)轉(zhuǎn)移的患者和29名無淋巴結(jié)轉(zhuǎn)移的患者,其中有淋巴結(jié)轉(zhuǎn)移的患者組大腸癌組織中FGF3的相對(duì)表達(dá)量為0.00057(0.00011,0.00178),無淋巴結(jié)轉(zhuǎn)移的患者組大腸癌組織中FGF3的相對(duì)表達(dá)量為0.00040(0.00014,0.00157),有淋巴結(jié)轉(zhuǎn)移的患者組大腸癌組織中FGF3的相對(duì)表達(dá)量稍高于無淋巴結(jié)轉(zhuǎn)移的患者組,兩組之間無統(tǒng)計(jì)學(xué)差異(p0.05,見fig.4、table.1)。5按照大腸癌dukes分期為51個(gè)大腸癌患者分組,可分為a期,b期,c期,d期。其中a期和b期的大腸癌患者有28人,c期和d期的大腸癌患者有23人。a期和b期的患者直腸癌組織相對(duì)表達(dá)量為0.00048(0.00017,0.00177),c期和d期的患者直腸癌組織相對(duì)表達(dá)量為0.00054(0.00011,0.00155),兩組之間無統(tǒng)計(jì)學(xué)差異(p0.05,見fig.5、table.1)。6以大腸癌腫瘤位置分組,其中直腸癌有31人,結(jié)腸癌20人,直腸癌組相對(duì)表達(dá)量為0.00054(0.00011,0.00137),結(jié)腸癌組相對(duì)表達(dá)量為0.00044(0.00013,0.00269),直腸癌組相對(duì)表達(dá)量稍高于結(jié)腸癌組,兩組之間無統(tǒng)計(jì)學(xué)差異(p0.05,見fig.6、table.1)。結(jié)論:1FGF3在51例患者癌旁組織中的表達(dá)明顯高于大腸癌組織,提示FGF3的表達(dá)差異可能與大腸癌的發(fā)生與發(fā)展具有相關(guān)性。2 FGF3在51例患者大腸癌組織中表達(dá)水平的高低與患者平均年齡、性別、區(qū)域淋巴結(jié)轉(zhuǎn)移情況、大腸癌的Dukes分期、腫瘤位置并無明顯相關(guān)性。
[Abstract]:Objective: colorectal cancer is one of the world's most common malignant tumors, the incidence of colorectal cancer showed a rising trend in recent years. The pathogenesis of colorectal cancer complex has not been fully elucidated, but many researchers believe that the incidence of colorectal cancer is caused by multiple factors and multiple gene interactions and the progressive development of the results. There are a large number of studies show that most human tumor occurrence, development process and FGF3 fibroblast growth factor 3 gene expression related to the differentiation and prognosis of malignant tumors. And this experiment by real-time fluorescence quantitative polymerase chain reaction (real-time PCR) expression in tumor tissues of patients with colorectal cancer and corresponding adjacent tissues FGF3 the amount of mRNA level, through the analysis of experimental data and clinical pathological data, study the relationship between FGF3 mRNA and colorectal cancer, for in-depth understanding of FGF3 in the pathogenesis of colorectal cancer in the play Provide a theoretical basis for the effect. Methods: 1 September 2015 ~2016 year in October 51 from the first hospital of Hebei Medical University, Department of general surgery of colorectal cancer and corresponding adjacent tissue specimens. No necrosis of colorectal cancer was defined as pathology, perforation and ulcer of primary colorectal cancer; carcinoma is defined as the distance 5cm above the edge of the tumor pathology confirm the non cancer tissue, and no necrosis, ulcer perforation and colorectal tissue. Fresh tissue specimens rapidly after placed after cold treatment 1.5ml EP tube, extraction and put in the -80 stored at.51 patients in the ultra low temperature freezer before the total RNA of any program of radiotherapy and chemotherapy of colorectal cancer.2 carcinoma is extracted in strict accordance with the American Invirotrogen company Trizol kit method. Then according to the U.S. company genecopoeia reverse transcription Kit Manual steps for reverse transcription, was detected by cDNA.3 real-time PCR of 51 colorectal cancer tissues and corresponding adjacent tissues CT, using GAPDH as internal control, calculation of FGF3mRNA in colorectal cancer tissue by 2- CT method, the relative expression in cancer tissue. The expression differences were compared between the two groups, and then grouping the pathological data of different, different groups were compared between carcinoma relative expression difference of.4 by SPSS19.0 and Prism 5 statistical software GraphPad, the analysis of experimental results, the measurement data to the median (four percentile), between the two groups using paired samples nonparametric test. P0.05 difference was statistically significant results. 1FGF3: in 51 cases of colorectal cancer in the relative expression of 0.00054 (0.00011,0.00154), the expression in cancer tissue was 0.00306 (0.00096,0.01170), expression of FGF3 in colorectal cancer tissues was significantly lower than in adjacent Tissue expression, the difference was statistically significant (P0.05, Fig.1) the average age of.251 patients is about 65 years old, the age group, the relative expression of which is less than the group of patients with FGF3 colorectal cancer at the age of 65 in the amount of 0.00087 (0.00011,0.00234), the age is equal to or greater than 65 years of relative expression of FGF3 in patients with colorectal cancer in the amount of 0.00050 (0.00011,0.00116). The relative expression of FGF3 in patients younger than 65 years old group in colorectal cancer patients is greater than or equal to the amount is slightly higher than that of group 65, but no significant difference between the two groups (P0.05, Fig.2, table.1,.3) by sex group, 51 cases of rectal cancer patients were divided into male group and female group were 33 male patients and 18 female patients, the relative expression of FGF3 in colorectal cancer in male group was 0.00040 (0.00011,0.00146), the relative expression of FGF3 in colorectal carcinoma in the female group was 0.00057 (0.00017,0.00246), female The relative expression of group FGF3 carcinoma is slightly higher than the male group, but no significant difference (P0.05, Fig.3, table.1).451 cases of colorectal cancer patients including 22 patients with lymph node metastasis and 29 without lymph node metastasis, including relative expression in patients with FGF3 colorectal cancer lymph node metastasis in the amount of 0.00057 (0.00011,0.00178), the relative expression of FGF3 in patients without lymph node metastasis group of colorectal cancer in the amount of 0.00040 (0.00014,0.00157), the relative expression of FGF3 in patients with colorectal cancer lymph node metastasis in quantity was slightly higher than that of patients with no lymph node metastasis, there was no significant difference between the two groups (P0.05 see Fig.4,.5, table.1) in colorectal cancer Dukes staging in 51 patients with colorectal cancer group, can be divided into a phase, B phase, C phase, D phase. The A and B of patients with colorectal cancer 28, C and D of patients with colorectal cancer and 23 people.A stage B patients Their relative expression of 0.00048 colorectal cancer (0.00017,0.00177), C and D in patients with rectal cancer relative expression quantity was 0.00054 (0.00011,0.00155), no significant difference between the two groups (P0.05, Fig.5, table.1).6 in colorectal tumor location group, which has 31 human colon cancer rectal cancer, 20 rectal cancer. Group relative expression quantity was 0.00054 (0.00011,0.00137), colon cancer group relative expression was 0.00044 (0.00013,0.00269), the relative expression in rectal cancer group was slightly higher than that of colon cancer group, no significant difference between the two groups (P0.05, Fig.6, table.1). Conclusion: the expression of 1FGF3 in 51 cases of cancer patients was significantly higher than that in the adjacent tissues colorectal cancer, FGF3 expression may have suggested that the expression level of patients with Ping Junnian's age, the relationship between the level of.2 FGF3 in 51 cases of patients with colorectal cancer occurrence and development of colorectal cancer and gender, regional lymph node metastasis There is no significant correlation between the Dukes staging of colorectal cancer and the location of the tumor.

【學(xué)位授予單位】：河北醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.34

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 Qin Zhou;Ke Li;Guo-Zhen Lin;Ji-Chuan Shen;Hang Dong;Yu-Ting Gu;Hua-Zhang Liu;;Incidence trends and age distribution of colorectal cancer by subsite in Guangzhou,2000-2011[J];Chinese Journal of Cancer;2015年08期

2 孫聰;柳勝生;蔡濱欣;吳巧敏;計(jì)鳳妹;朱美英;;上海市松江區(qū)社區(qū)自然人群大腸癌篩查結(jié)果分析[J];中國(guó)初級(jí)衛(wèi)生保健;2014年07期

3 賈聰聰;張小晶;黃陳平;林林;趙淑江;靳大慶;;斑馬魚胚胎發(fā)育過程中FGF3基因的表達(dá)[J];中國(guó)細(xì)胞生物學(xué)學(xué)報(bào);2012年04期

4 王新穎;;對(duì)當(dāng)前大腸癌篩查策略和方法的評(píng)析[J];現(xiàn)代消化及介入診療;2011年02期

5 張孝衛(wèi);黃麗華;杜雪;李鐵軍;王兵;王麗珍;史世娟;;RNA干擾HT-29細(xì)胞FGF3基因表達(dá)對(duì)其生長(zhǎng)和遷移速度的影響[J];現(xiàn)代腫瘤醫(yī)學(xué);2009年11期

6 吳曉媚;杜金鋒;王章奇;黃新愛;;Kai1在大腸癌中的表達(dá)[J];當(dāng)代醫(yī)學(xué);2009年19期

7 陳勇;劉巍;;惡性腫瘤微血管研究進(jìn)展[J];中華腫瘤防治雜志;2007年11期

8 張永海;謝丹;羅俊航;陳煒;陳凌武;徐慶春;;膀胱移行細(xì)胞癌中成纖維細(xì)胞生長(zhǎng)因子3基因表達(dá)與擴(kuò)增的臨床意義[J];中華醫(yī)學(xué)雜志;2006年36期

9 江現(xiàn)強(qiáng);劉志明;赫軍;陸云飛;;甲狀腺癌中血管內(nèi)皮生長(zhǎng)因子、成纖維細(xì)胞生長(zhǎng)因子3的表達(dá)及意義[J];西安交通大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2005年06期

10 邵根澤,任運(yùn)生,張少英,溫博貴;p53基因突變、int-2基因擴(kuò)增與食管癌的關(guān)系[J];中華醫(yī)學(xué)遺傳學(xué)雜志;1997年05期

，

本文編號(hào)：1639288